Furiex ready to progress MuDelta for IBS to Phase III
This article was originally published in Scrip
Furiex Pharmaceuticals has reported positive data from a Phase II proof-of-concept trial investigating its diarrhoea-predominant irritable bowel syndrome (IBS-D) treatment, MuDelta. Of note, the company said it had also performed some additional study analyses, based on discussions with the US FDA about appropriate endpoints in this indication, which could also be used in future Phase III trials.
You may also be interested in...
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.